Atara Biotherapeutics Inc

ATRA

$14.65

+12.59% (1 year change)

Avg closing price

Price range

Market Cap

$1.04 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

-

Total revenue in the last quarter.

Net Income

$-77.5 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$-5.01

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-2.8x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-78 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

393

The number of full time employees.

Revenue & Earnings

Balance Sheet

Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

News

Brokerages Expect Atara Biotherapeutics Inc (NASDAQ:ATRA) to Post -$1.10 EPS

Brokerages Expect Atara Biotherapeutics Inc (NASDAQ:ATRA) to Post -$1.10 EPS

Brokerages expect Atara Biotherapeutics Inc (NASDAQ:ATRA) to report earnings per share (EPS) of ($1.10) for the current quarter, according to Zacks Investment Research. Zero analysts have provided ...

The Olympia Report The Olympia Report, 3 days ago
Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-CelĀ® Expanded Access Program in e-Poster at ESMO 2020 Virtual Congress

Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-CelĀ® Expanded Access Program in e-Poster at ESMO 2020 Virtual Congress

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transform...

Business Wire Business Wire, about 1 month ago
Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188

Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments...

Business Wire Business Wire, about 1 month ago